Testing a thyroid hormone drug with chemo for relapsed medulloblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have medulloblastoma that has returned or worsened after standard therapy.
- You are between 1 and 25 years old.
- You have disease visible on MRI or in spinal fluid (cf-DNA positive).
- You have adequate organ function (blood counts, kidney, liver, heart, and adrenal glands).
- You have not had prior treatment with exactly the same chemotherapy combination tested here (BIT regimen).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
This trial tests whether adding arsenic trioxide to standard chemotherapy can help children whose medulloblastoma has come back or is hard to treat, especially if the tumor has certain genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.